valuation de l'impact du programme d'immunisation avec le vaccin pneumococcique conjugu et le vaccin influenza inactiv chez les enfants du Nunavik

In the Nunavik region (province of Quebec, Canada), hospitalizations for pneumonia are far more frequent than in the rest of Quebec and it is estimated that a quarter of all children in the region have a hearing deficit by age 5. In spring 2002, a routine immunization program for newborns using the 7-valent pneumococcal conjugate vaccine (7-PCV) was introduced, along with a catch-up program for children between the ages of two months and 5 years. In fall 2003, the decision was made to offer a trivalent inactivated influenza vaccine (TIV) to all children aged 6-23 months. The goal of the study is to evaluate the impact of this dual vaccination program and to study for the first time the ability of 7-PCV combined with TIV to prevent respiratory infections and otitis sequelae in a highly vulnerable population. It involves the retrospective follow-up to age 5 of 12 birth cohorts, namely children born between 1994 and 2005.